OneDigital Investment Advisors LLC Cuts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

OneDigital Investment Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,974 shares of the company's stock after selling 412 shares during the period. OneDigital Investment Advisors LLC's holdings in Eli Lilly and Company were worth $9,890,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of LLY. Avantax Planning Partners Inc. increased its position in Eli Lilly and Company by 11.2% in the first quarter. Avantax Planning Partners Inc. now owns 5,342 shares of the company's stock worth $4,412,000 after buying an additional 538 shares during the last quarter. Silver Oak Securities Incorporated increased its holdings in Eli Lilly and Company by 12.5% in the 1st quarter. Silver Oak Securities Incorporated now owns 2,784 shares of the company's stock worth $2,290,000 after acquiring an additional 309 shares during the last quarter. Calamos Wealth Management LLC raised its stake in Eli Lilly and Company by 8.5% in the 1st quarter. Calamos Wealth Management LLC now owns 30,691 shares of the company's stock valued at $25,348,000 after acquiring an additional 2,407 shares during the period. Cohen Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 10.4% during the first quarter. Cohen Investment Advisors LLC now owns 10,710 shares of the company's stock valued at $8,845,000 after purchasing an additional 1,006 shares during the last quarter. Finally, Sitrin Capital Management LLC boosted its position in Eli Lilly and Company by 0.3% during the first quarter. Sitrin Capital Management LLC now owns 6,644 shares of the company's stock worth $5,488,000 after purchasing an additional 22 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.0%

Shares of Eli Lilly and Company stock traded up $0.32 on Friday, hitting $779.60. The stock had a trading volume of 1,450,772 shares, compared to its average volume of 3,664,838. The stock's 50-day simple moving average is $773.61 and its two-hundred day simple moving average is $799.72. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a market cap of $738.85 billion, a price-to-earnings ratio of 63.43, a PEG ratio of 1.14 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the business earned $2.58 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LLY. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.